Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance ...

Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth SAN ...

Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...

When cells proliferate, genomic DNA is precisely duplicated once per cell cycle. Abnormalities in this DNA replication process can cause alterations in genomic DNA, promoting cellular ageing, cancer, ...

Cloudflare Inc. has acquired Replicate Inc., a startup with software that makes it easier to deploy artificial intelligence models in production. The companies announced the transaction today without ...

Baby boomers hold more than $85 trillion in assets, making them the richest generation by far. New research explores the extraordinary rise in their good fortunes — one that experts say successive ...

Cloudflare (NET) announced it has reached an agreement to acquire Replicate, which will give developers on its Workers platform access to tens of thousands of artificial intelligence models. Replicate ...

SAN FRANCISCO--(BUSINESS WIRE)--Cloudflare, Inc. (NYSE: NET), the leading connectivity cloud company, today announced it has agreed to acquire Replicate, an AI platform that makes it easy for ...

Aug 28 (Reuters) - Replicate Bioscience will partner with Novo Nordisk (NOVOb.CO), opens new tab to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other ...

Novo Nordisk has both internal research and external alliances pursuing new drugs that could shape the next generation of metabolic medicines. The pharmaceutical giant’s latest move is a partnership ...

As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a ...